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Abstract
Background: Constipation is a frustrating symptom affecting 3% of children worldwide. Randomised controlled
trials show that both polyethylene glycol and lactulose are effective in increasing defecation frequency in children
with constipation. However, in 30–50%, these children reported abdominal pain, bloating, flatulence, diarrhoea,
nausea and bad taste of the medication. Two recent studies have shown that the fermented dairy product
containing Bifidobacterium lactis strain DN-173 010 is effective in increasing stool frequency in constipation-
predominant irritable bowel syndrome patients with a defecation frequency < 3/week and in constipated women
with a defecation frequency < 3/week. Goal of this study is to determine whether this fermented dairy product
is effective in the treatment of constipated children with a defecation frequency < 3/week.
Methods/design: It is a two nation (The Netherlands and Poland) double-blind, placebo-controlled randomised
multicentre trial in which 160 constipated children (age 3–16 years) with a defecation frequency <3/week will be
randomly allocated to consume a fermented dairy product containing Bifidobacterium lactis DN-173 010 or a
control product, twice a day, for 3 weeks. During the study all children are instructed to try to defecate on the
toilet for 5–10 minutes after each meal (3 times a day) and daily complete a standardized bowel diary. Primary
endpoint is stool frequency. Secondary endpoints are stool consistency, faecal incontinence frequency, pain during
defecation, digestive symptoms (abdominal pain, flatulence), adverse effects (nausea, diarrhoea, bad taste) and
intake of rescue medication (Bisacodyl). Rate of success and rate of responders are also evaluated, with success
defined as ≥ 3 bowel movements per week and ≤1 faecal incontinence episode over the last 2 weeks of product
consumption and responder defined as a subject reporting a stool frequency ≥ 3 on the last week of product
consumption. To demonstrate that the success percentage in the intervention group will be 35% and the success
percentage in the control group (acidified milk without ferments, toilet training, bowel diary) will be 15%, with
alpha 0.05 and power 80%, a total sample size of 160 patients was calculated.
Conclusion: This study is aimed to show that the fermented dairy product containing Bifidobacterium lactis strain
DN-173 010 is effective in increasing stool frequency after 3 weeks of product consumption in children with
functional constipation and a defecation frequency < 3/week.
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Background
Chronic constipation is a common problem in childhood
with an estimated prevalence of 3% in the western world
[1]. Constipation is a debilitating condition characterized
by infrequent painful defecation, faecal incontinence and
abdominal pain. It causes distress to child and family and
results in severe emotional disturbance and family dis-
cord. The pathophysiology underlying functional consti-
pation is undoubtedly multi-factorial, and not well
understood. Withholding behaviour is probably the
major cause for the development of constipation and
might be caused by the previous production of a large,
hard painful stool, anal fissures, a primarily behavioural
mechanism or the resistance to go to another toilet than
their own [2]. A study in a tertiary hospital showed that
despite intensive medical and behavioural therapy, 30%
of the patients who developed constipation before the age
of 5 years continued to have severe complaints of consti-
pation, infrequent painful defecation and faecal inconti-
nence, beyond puberty [3].
Presently, there is no proper therapy available, mainly due
to a lack of pathophysiological insight. In a recently pub-
lished systematic review on the effect of laxative treatment
and dietary measures in childhood constipation, the
authors found insufficient evidence supporting that laxa-
tive treatment is better than placebo in children with con-
stipation due to a lack of placebo controlled trials [4].
Furthermore, RCT's performed in children with constipa-
tion showed that both polyethylene glycol (PEG) and lac-
tulose increased defecation frequency and decreased
faecal incontinence frequency. However, in 30–50% of
the patients using these compounds, adverse side-effects
were observed such as: abdominal pain, bloating, flatu-
lence, diarrhoea, nausea and bad taste [4,5]. Low compli-
ance is probably of major importance with respect to the
low percentage of children cured after 6 months of laxa-
tive treatment, suggesting that development of new treat-
ment strategies is of great importance.
Rationale for the efficacy of the fermented dairy product 
containing Bifidobacterium lactis DN-173 010 in 
childhood constipation
Probiotics are defined as live micro-organisms which
when administered in adequate amounts confer a health
benefit on the host [6]. It is suggested that there is a dys-
biosis in the gut flora in constipated patients which might
be improved by probiotics [7]. This is important because
colonic microflora influences the peristalsis of the colon.
Furthermore, Bifidobacteria can lower the pH of the colon
by producing lactic, acetic and other acids. A lower pH
enhances peristalsis of the colon and subsequently
decreases colonic transit time which is beneficial in the
treatment of constipation [7,8]. Activia® is a fermented
milk manufactured with lactic cultures including yoghurt
starter cultures (Lactobacillus bulgaricus and Streptococcus
thermophilus) and a specific probiotic strain, Bifidobacte-
rium lactis DN-173 010. Recently, studies have shown that
this fermented milk significantly decreased transit time in
young and elderly healthy adults [9-13] and in constipa-
tion-predominant IBS patients [14]. Moreover, a recent
randomised double-blind controlled trial in IBS patients
with constipation showed a significant increase, as com-
pared to controls, in stool frequency over the 6-weeks
product consumption in the subgroup of patients with a
defecation frequency <3/week [15]. Another recent ran-
domised double-blind controlled study demonstrated a
significant increase of stool frequency in constipated
women with a defecation frequency <3/week following
consumption of the fermented milk for 2 weeks compared
to control group [16]. In a small pilot study in The Neth-
erlands, 8 consecutive children with untreated constipa-
tion with a defecation frequency < 3 per week and hard
stools were treated with the fermented milk 2 times/day
for one month. A normalization of the defecation fre-
quency and improvement from hard to soft stools were
seen in five of them. In the three other children no
improvement was found. None of the children reported
side effects. Based on these data, a multi-centre RCT is
required to assess whether Activia® is effective in the treat-
ment of childhood constipation. We hypothesize that the
compliance increases by taking fermented milk contain-
ing Bifidobacterium lactis DN-173 010. If this study indeed
shows a significant better effect of active product com-
pared to control product, this will change the treatment of
newly diagnosed children with constipation. This paper
describes the rationale and the design of this study.
Methods/design
Study objectives
The study objective is to show that the fermented milk
containing Bifidobacterium lactis DN-173 010 is effective in
increasing defecation frequency after 3 weeks of product
consumption in children with functional constipation.
Primary endpoint
The primary endpoint is the stool frequency change from
baseline to 3 weeks of product consumption.
Secondary endpoints
Secondary endpoints are:
- Stool frequency over 3 weeks and at week 1 and 2 of
product consumption.
- Stool consistency over 3 weeks and per week of product
consumption.
- Frequency of episodes of faecal incontinence over 3
weeks and per week of product consumption.BMC Pediatrics 2009, 9:22 http://www.biomedcentral.com/1471-2431/9/22
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- Pain during defecation over 3 weeks and per week of
product consumption.
- Digestive symptoms: abdominal pain and flatulence
over 3 weeks and per week of product consumption.
- Adverse effects: nausea, diarrhoea and bad taste over 3
weeks and per week of product consumption.
- Intake of Bisacodyl over 3 weeks and per week of product
consumption.
- Rate of success with success defined as 3 or more bowel
movements per week and less than 1 faecal incontinence
episode in 2 weeks over the last 2 weeks of product con-
sumption
- Rate of responders with a responder defined as a subject
who reports a stool frequency = 3 on the last week of prod-
uct consumption
Design
Double-blind, placebo-controlled randomised multicen-
tre, two nation (the Netherlands and Poland) trial.
Setting
Children able to participate in this study will be recruited
in two countries in Europe: from three academic hospitals
(Academic Medical Centre Amsterdam, University Hospi-
tal Groningen, The Netherlands and the Medical Univer-
sity of Warsaw, Poland), 12 Dutch non-academic
hospitals and general practitioners (region of Rotterdam)
in The Netherlands.
Patients
A total of 160 functional constipated children, boys and
girls, aged from 3 to 16 years will be randomised.
Study products
Test product: fermented milk Activia® (125-g pot) manu-
factured with lactic cultures including yoghurt starter cul-
tures (Lactobacillus delbrueckii ssp.  bulgaricus  and
Streptococcus thermophilus) [at least 1,2 × 109 colony form-
ing units (cfu) per pot] and a specific strain, Bifidobacte-
rium lactis DN-173 010 [at least 6 × 109cfu per pot].
Control: milk-based non-fermented dairy product (125-g
pot) without probiotics and with low content of lactose <
4 g/pot as in the test product.
Every patient has to take two pots of study products per
day (test or control) to be consumed in two times (one at
the breakfast and one at the evening meal) for 3 consecu-
tive weeks. During the entire study, all children are
instructed to try to defecate on the toilet for 5–10 minutes
after each meal (3 times a day) and to complete daily a
standardized bowel diary. They were also instructed not to
consume other fermented dairy products or yoghurts dur-
ing all the study.
Eligibility criteria
Inclusion criteria
-Children (boys and girls) aged from 3 to 16 years
-Children with a diagnosis of functional constipation
according to Rome III criteria [17]:
- subjects must present defecation frequency < 3/week
and:
- subjects must present 1 or more of the following criteria:
faecal incontinence > 1/week
large amount of stools which clog the toilet
painful defecation
withholding behaviour
abdominal or rectal faecal impaction upon physical exam-
ination
-Children with a diagnosis of functional constipation
according to Rome III criteria fulfilled for the last 2
months
-Children with usual consumption of dairy products and
ready to consume 2 pots per day
-Children having given written consent to take part in the
study (in The Netherlands: children and parents for chil-
dren above 12 years and only parents for children under
12 years; in Poland: children and parents for children
above 16 years and only parents for children under 16
years).
Non-inclusion criteria
-Children with a diagnosis of IBS according to Rome III
criteria
-Children treated for constipation less than 2 weeks before
intake in the study
-Children with mental retardation or metabolic disease
(hypothyroidism)
-Children with Hirschsprung's disease or spinal anoma-
lies or anorectal pathology
-Children who underwent gastro-intestinal surgeryBMC Pediatrics 2009, 9:22 http://www.biomedcentral.com/1471-2431/9/22
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-Children with functional non-retentive faecal inconti-
nence
-Children with lactose intolerance or known allergy to
product component (milk protein for example)
-Children who started a medication with antibiotics in the
prior month
-Children receiving medication influencing gastrointesti-
nal motility (for examples Cisapride, Motilium, Erythro-
mycin, laxatives, Loperamide)
During the study it is not allowed to consume any other
fermented dairy product or yoghurt.
Randomisation criteria (checked at visit 2)
After inclusion in the study, all patients with a defecation
frequency < 3 per week between visit 1 and visit 2 and who
did not use any laxative between V1 and V2 are ran-
domised at visit 2.
Ethics, informed consent
This study is conducted in accordance with the principles
of the Declaration of Helsinki and 'good clinical practice'
guidelines (ICH E6). The independent ethics committee
of all participating hospitals approved the final protocol.
Written informed consent is obtained from the patient
and/or parents before inclusion in the trial at visit 1.
Safety
To date, no adverse events associated with the consump-
tion of the fermented milk containing Bifidobacterium lac-
tis DN-173 010 were observed in clinical studies done
with this product. During consumption of the study prod-
uct, both the patient and medical staff are asked to register
any potential side effect or adverse event. All adverse
events will be monitored and discussed by an independ-
ent Clinical Research Organisation.
Statistical analysis
Intention-to-treat
The analysis will be performed on the basis of an inten-
tion-to-treat (ITT) population and with respect to ITT
principles. Also a per-protocol (PP) analysis will be per-
formed.
Sample size
We assume that the success percentage in the intervention
group (fermented milk containing Bifidobacterium lactis
DN-173 010, toilet training, bowel diary) will be 35% and
the success percentage in the control group (acidified milk
without ferments, toilet training, bowel diary) will be
15%, and "alpha" is 0.05 and the power ("beta") is 80%.
The choice of 15% is justified by a previous study of van
der Plas et al. showing that 15% of children with
untreated chronic defecation problems can be helped by
an approach of toilet training and a daily bowel diary
alone[18]. The total number of randomised subjects in
this study has to be 146. To allow withdrawal a number of
160 subjects will be randomised. This means each group
consists of 80 subjects. The number of randomised sub-
jects per country will be 80 (± 20%).
Randomisation
The assignment of subjects to test or control groups will
be carried-out by randomisation in well balanced blocks
performed by Danone Research prior to the study onset.
These randomisation lists (one per country) used for
assigning each subject to a treatment group will be pre-
pared and kept confidentially. It will be forwarded to the
person responsible of the preparation of study products
and their labelling. Subjects will be then included sequen-
tially in both countries per randomisation lists (incremen-
tally by randomisation number by the IWRS system).
Blinding
The two treatments, fermented milk containing Bifidobac-
terium lactis DN-173 010 and control product, are identi-
cal in weight, colour, smell, taste and package. All doctors,
research staff and patients involved are unaware of the
treatment administered to the patient.
Treatment program
See figure 1 for the study planning. The total duration of
the study is approximately 5 weeks for each subject. Each
patient will attend 3 clinic appointments: Inclusion visit
V1 (baseline), randomisation visit (V2) and clinical eval-
uation at weeks 3 (V3). When a child is eligible for inclu-
sion, a list of non-authorized products will be discussed
with the child and parents at visit 1. The first 8 days will
be used to obtain baseline values for the outcome param-
eters. After 3 days of enemas, the 3 subsequent weeks (day
0 to day 20) will constitute the treatment phase. The sub-
jects will receive and consume 2 products (test or control
product) per day. Between days 7 and 10, the subjects will
receive new products, to be consumed during the second
part of the treatment period, to ensure consumption
before end of shelf-life of the products. They will cease
consumption of the study product at the end of week 3
(day 20) and will then have their last visit on day 21. Dur-
ing the treatment phase, patients can take Bisacodyl 5 mg
if they have no defecation for 3 consecutive days.
Frequency of defecation, frequency of faecal incontinence
episodes, frequency of toilet training, self-evaluation of
digestive symptoms (abdominal pain and flatulence) and
of adverse effects (nausea, diarrhoea and bad taste) will be
assessed daily during the entire study using a subject diary.
Stool consistency and pain during defecation will be
assessed for each passed stool using the same paper diary.
The subject's diary will be also used to record the dailyBMC Pediatrics 2009, 9:22 http://www.biomedcentral.com/1471-2431/9/22
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consumption of the study products, any unauthorised
products and Bisacodyl and any other concomitant treat-
ment.
Monitoring
Independent Clinical Research Associates (CRA) will visit
at least twice every site in order to monitor all the patients'
data.
Follow-up
After finishing the study, all children will get an appoint-
ment at the outpatient clinic in their hospital for treat-
ment of their constipation.
Discussion
Only children with a defecation frequency < 3/week will
be included in this study. This seems inconsistent with the
ROME-III definition for functional constipation, since 2
out of 6 defecation related criteria should be present.
However, in our experience approximately 100% of chil-
dren with a defecation frequency < 3/week fulfil one or
more other symptoms of the Rome definition for func-
tional constipation. An advantage of this strategy is that a
more homogenous population of children with func-
tional constipation will be included. Furthermore, a
recent double-blind controlled trial showed beneficial
effect of the fermented milk containing Bifidobacterium
lactis DN-173 010 in increasing stool frequency in IBS
patients with constipation and a defecation frequency <3/
week and another one showed an increase in stool fre-
quency in constipated women also with a defecation fre-
quency <3/week following consumption of this product.
Recently 4 human double-blind randomised studies using
1–3 portions of fermented milk containing Bifidobacte-
rium lactis strain DN-173 010 all reported a significant
reduction of transit time in healthy subjects, especially in
those with slow transit[7,9,11-13], and also in IBS
patients with constipation[14]. No adverse effects associ-
ated with the consumption of the fermented milk con-
taining Bifidobacterium lactis DN-173 010 were observed
in clinical studies done with this product. In the healthy
adults, three portions per day proved to be more effective
than two, whereas two portions appeared more effective
than one. In this study we have chosen for two portions of
fermented milk containing Bifidobacterium lactis DN-173.
In these studies a reduction in transit time was observed
within two weeks. Therefore we expect that three weeks of
ingestion of the fermented milk containing Bifidobacte-
rium lactis DN-173 010 are sufficient to determine its
effectiveness.
Bisacodyl is a laxative of the triarylmethane group, which
is hydrolyzed in the bowel by local enzymes into the
Study planning in days (D-11 to D+21) Figure 1
Study planning in days (D-11 to D+21).
Consumption of the study product : 2 pots of Activia® or Control product per day
Inclusion
Visit V1
D- 1 1
Evaluation Visit
V3
D +21 [+2]
Randomisation Visit
V2
D 0
Enema performed daily during 3 days
Authorisation to consume Bisacodyl if no defecation in the last  3 days
Food restrictions : no consumption of other fermented dairy prod ucts or yoghurts
-2 -1
D-3 [+2]
Frequency of defecation, episodes of fecal incontinence and toil et training: Daily self-evaluation by the 
children and/or the parents during the entire study.
Consistency of stools and pain during defecation : Self-evaluation for each passed stool by the children 
and/or the parents during the entire study.
Digestive symptoms (abdominal pain and flatulence) and adverse e ffects (nausea, diarrhoea and bad 
taste): Daily self-evaluation by the children and/or the parents during the entire  study.
Intake of Bisacodyl: Daily self-evaluation by the children and/or the parents during the entire  study.
D +20
Products delivery to the subjects
Consumption of the study product : 2 pots of Activia® or Control product per day
Inclusion
Visit V1
D- 1 1
Evaluation Visit
V3
D +21 [+2]
Randomisation Visit
V2
D 0
Enema performed daily during 3 days
Authorisation to consume Bisacodyl if no defecation in the last  3 days
Food restrictions : no consumption of other fermented dairy prod ucts or yoghurts
-2 -1
D-3 [+2]
Frequency of defecation, episodes of fecal incontinence and toil et training: Daily self-evaluation by the 
children and/or the parents during the entire study.
Consistency of stools and pain during defecation : Self-evaluation for each passed stool by the children 
and/or the parents during the entire study.
Digestive symptoms (abdominal pain and flatulence) and adverse e ffects (nausea, diarrhoea and bad 
taste): Daily self-evaluation by the children and/or the parents during the entire  study.
Intake of Bisacodyl: Daily self-evaluation by the children and/or the parents during the entire  study.
D +20
Products delivery to the subjects
D +13BMC Pediatrics 2009, 9:22 http://www.biomedcentral.com/1471-2431/9/22
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active agent bis-(p-hydroxyphenyl)-pyridyl-2-methane
(BHPM). Bisacodyl, in contrast to polyethylene glycol and
lactulose, directly stimulates colonic peristalsis and does
not interfere with the microflora of the gut. Therefore
Bisacodyl has been chosen as rescue medication in case
children do not defecate for three consecutive days during
the study period.
Conclusion
This is the first double-blind, placebo-controlled ran-
domised multicentre trial that aims to show that the fer-
mented milk containing Bifidobacterium lactis DN-173 010
is effective in increasing stool frequency after 3 weeks of
product consumption in children with functional consti-
pation.
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